This study aimed to present our single-center experience of anakinra and canakinumab treatment in patients with Familial Mediterranean fever (FMF). This study included 48 patients who were treated with anti-interleukin-1 (antiIL-1) treatment for at least six months. Initially, all patients with colchicineresistant or intolerant FMF were received anakinra treatment. Then those resistant to anakinra were given canakinumab treatment. Of the 48 (female/male:29/19) patients using anti-IL-1, their age was 31.2 ± 10.7 years, the duration of drug use was 15±8 months. 30 patients were already using anakinra and 18 patients were using canakinumab. Treatment was found to be switched to canakinumab in 9 patients due to non-adherence to daily injection, and inadequate response to anakinra in 9 patients. After the anti-IL-1 treatment the number of attacks, erythrocyte sedimentation rate, C-reactive protein, fibrinogen levels, colchicine dose and proteinuria (for all p<0.001) were decreased. Anti-IL-1 treatment is effective for controlling attacks and reducing proteinuria in patients with colchicine-resistant or intolerant FMF. In addition, canakinumab appears to be an alternative treatment option when there is a inconvenience to daily injection or resistance to anakinra treatment.
familial Mediterranean fever interleukin-1 inhibition anakinra canakinumab
The authors would like to thank Enago (www.enago.com) for English language review.
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Clinical Research |
Yazarlar | |
Yayımlanma Tarihi | 26 Ocak 2021 |
Gönderilme Tarihi | 7 Nisan 2020 |
Kabul Tarihi | 24 Ağustos 2020 |
Yayımlandığı Sayı | Yıl 2021 Cilt: 38 Sayı: 1 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.